Please login to the form below

Not currently logged in
Email:
Password:

hepatocellular carcinoma

This page shows the latest hepatocellular carcinoma news and features for those working in and with pharma, biotech and healthcare.

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been ... submitted for approval for hepatocellular carcinoma, a

Latest news

More from news
Approximately 1 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.

  • Pharma deals in April 2015 Pharma deals in April 2015

    deacetylase (HDAC) inhibitor in all oncological indications, in particular hepatocellular carcinoma in Asia Pacific (excluding Japan).

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). ... However the platform technology also has potential

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics